Instrument Inactif

Autres langues Taxus Cardium Pharmaceuticals Group Inc OTC Bulletin Board

Actions

CRXM

US1419163043

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

30/03/22	Gene Biotherapeutics, Inc. L'auditeur soulève un doute sur la pérennité de l'entreprise	CI
03/09/21	Gene Biotherapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2020	CI

Autres langues

14/04/22	GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
30/03/22	GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
30/03/22	Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
27/10/21	GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
03/09/21	GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
03/09/21	Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
09/08/21	GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)
05/08/21	GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
28/07/21	GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
28/07/21	Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board
26/04/21	GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
26/04/21	Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product
23/04/21	GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
28/05/20	GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
28/05/20	Gene Biotherapeutics, Inc. Announces Management Changes
28/05/20	Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer
22/05/20	Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC
20/03/19	Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors
13/09/18	Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc
08/01/18	Gene Biotherapeutics Mulls Acquisitions
13/06/17	Taxus Cardium Pharmaceuticals Group Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Application
12/06/17	Cardium Therapeutics : Angionetics To Present At Marcum 2017 MicroCap conference In New York City
05/06/17	Cardium Therapeutics : Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, China
01/03/17	Taxus Cardium Mulls Acquisitions
09/02/17	Cardium Therapeutics : Angionetics To Present At The Biotechnology Industry Organization CEO & Investor Conference At The Waldorf Astoria New York City